| __timestamp | Sarepta Therapeutics, Inc. | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 94103000 | 22622695 |
| Thursday, January 1, 2015 | 146194000 | 24863028 |
| Friday, January 1, 2016 | 130000 | 21351001 |
| Sunday, January 1, 2017 | 7353000 | 53837297 |
| Monday, January 1, 2018 | 34193000 | 16080096 |
| Tuesday, January 1, 2019 | 56586000 | 18525736 |
| Wednesday, January 1, 2020 | 63382000 | 2024000 |
| Friday, January 1, 2021 | 97049000 | 2548000 |
| Saturday, January 1, 2022 | 139989000 | 61556000 |
| Sunday, January 1, 2023 | 150343000 | 188157000 |
Cracking the code
In the competitive world of biotechnology, cost efficiency can be a decisive factor for success. This analysis compares the cost of revenue efficiency between Sarepta Therapeutics, Inc. and Telix Pharmaceuticals Limited from 2014 to 2023. Over this period, Sarepta's cost of revenue has shown significant fluctuations, peaking in 2023 with a 60% increase from its 2014 figures. Meanwhile, Telix Pharmaceuticals experienced a dramatic rise, with its cost of revenue in 2023 being over eight times higher than in 2014. Notably, 2016 was an outlier year for Sarepta, with a minimal cost of revenue, indicating potential strategic shifts or operational changes. This data highlights the dynamic nature of the biotech industry, where companies must continuously adapt to maintain financial efficiency. Understanding these trends is crucial for investors and stakeholders aiming to navigate the complexities of the biotech sector.
Comparing Cost of Revenue Efficiency: Novartis AG vs Telix Pharmaceuticals Limited
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Sarepta Therapeutics, Inc.
BeiGene, Ltd. vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for BeiGene, Ltd. and Telix Pharmaceuticals Limited
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Grifols, S.A.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Perrigo Company plc's Expenses
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Telix Pharmaceuticals Limited
Comparing Cost of Revenue Efficiency: Telix Pharmaceuticals Limited vs Veracyte, Inc.
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and MorphoSys AG's Expenses
Cost of Revenue Trends: Telix Pharmaceuticals Limited vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Telix Pharmaceuticals Limited vs Geron Corporation
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Supernus Pharmaceuticals, Inc.